A clinical trial has revealed that Novo Nordisk's (NYSE: NVO) weight loss drug Wegovy significantly decreases the risk of serious heart complications.
According to CNBC, the Select study tested Wegovy on around 17,500 individuals with obesity and heart disease. These participants did not have diabetes. The study found that weekly Wegovy injections reduced the overall risk of heart attack, stroke and death from cardiovascular causes by 20%.
Dr. Robert Kushner, a professor of medicine in endocrinology at Northwestern University Feinberg School of Medicine, told ...